Skip to main content

Table 1 Selected baseline and demographic characteristics (N = 32).

From: Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

Characteristic

Mean (SD)

Age (y)

71.8 (7.5)

Length of symptoms (mo)*

29.6 (18.3)

Baseline MMSE

21.3 (4.1)

Baseline GDS

3.7 (0.78)

  1. MMSE = Mini-Mental Status Examination; GDS = Geriatric Deterioration Scale.
  2. *Length of symptoms prior to enrollment in the double-blind study.
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us